DLL3在神经内分泌和非神经内分泌肿瘤中的表达模式揭示了广泛的治疗靶点机会。
Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting.
作者信息
Lozada John R, Elliott Andrew, Evans Mark G, Wacker James, Storey Kathleen M, Egusa Emily A, Zorko Nicholas A, Kumar Akhilesh, Crymes Anthony, Heath Elisabeth I, Carneiro Benedito A, Soares Heloisa P, Cichocki Frank, Miller Jeffrey S, Lou Emil, Beltran Himisha, Antonarakis Emmanuel S, Ryan Charles J, Hwang Justin H
机构信息
Division of Hematology, Oncology, and Transplantation, University of Minnesota-Twin Cities, Minneapolis, Minnesota.
Masonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, Minnesota.
出版信息
Cancer Res Commun. 2025 Feb 1;5(2):318-326. doi: 10.1158/2767-9764.CRC-24-0501.
DLL3-targeted therapies have recently shown robust clinical efficacy in aggressive neuroendocrine cancers, positioning them to fulfill a great unmet need in these settings. Here, we examine the clinical and biological correlates of DLL3 expression in both neuroendocrine and non-neuroendocrine cancers. Our findings may stimulate the development and application of DLL3-targeted therapies, as well as other precision therapies, in neuroendocrine cancers and beyond.
靶向DLL3的疗法最近在侵袭性神经内分泌癌中显示出强大的临床疗效，使其有望满足这些情况下尚未满足的巨大需求。在此，我们研究了神经内分泌癌和非神经内分泌癌中DLL3表达的临床和生物学相关性。我们的研究结果可能会促进靶向DLL3疗法以及其他精准疗法在神经内分泌癌及其他癌症中的开发和应用。
Zotero 插件